Actively Recruiting
Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination
Led by Bioaster · Updated on 2025-03-07
400
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying onchocerciasis (river blindness), a leading cause of infectious blindness worldwide, mainly affecting Africa. The study aims to develop and evaluate a new rapid diagnostic test to improve detection of onchocerciasis, especially in areas where related parasitic infections like loiasis and mansonellosis occur. This is part of the World Health Organization's 2021-2030 roadmap to eliminate onchocerciasis transmission by improving diagnostic tools. The study involves cross-sectional research conducted over one year in Cameroon, targeting adults 18 and older. Participants include people without filariasis and those mono-infected with Onchocerca volvulus, Loa loa, or Mansonella perstans. After screening and consent, blood and feces samples are collected from participants. Blood is processed and stored at very low temperatures before being sent to a laboratory for development and evaluation of the new diagnostic test. Participants will undergo initial screening to diagnose filarial infections, followed by sample collection if eligible. Researchers will update data on disease prevalence and assess the performance of the new test over 52 weeks. The study includes careful sample handling and transport, with results intended to support onchocerciasis control programs. The total involvement includes screening, sample collection, and follow-up during the study period.
CONDITIONS
Brief Title
Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subjects informed of the objectives of the study and who signed a consent form
- Subjects without filariasis (for control subjects), or
- Subjects mono-infected with Onchocerca volvulus, or
- Subjects mono-infected with Loa loa, or
- Subjects mono-infected with Mansonella perstans or alternatively co-infected with Mansonella perstans and Loa loa
You will not qualify if you...
- Pregnant or breast-feeding women
- Subjects having taken antihelminthic treatment less than 6 months before the inclusion date
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit (in-person)
Duration - Up to 52 weeks
Participants provide blood and feces samples for the development and validation of a new rapid diagnostic test for onchocerciasis.
1 visit for sample collection (in-person)
Trial Site Locations
Total: 1 location
1
Higher Institute for Scientific and Medical Research
Yaoundé, Cameroon, 5797
Actively Recruiting
Research Team
M
Marie KOENIG
M
Marion DARNAUD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here